Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

J&J Expands Puerto Rico Factories

October 1, 2012 6:36 pm | by The Associated Press | News | Comments

Johnson & Johnson and the governor of Puerto Rico jointly announced an expansion of four existing plants that will add 308 jobs. The company based in New Brunswick, New Jersey will be investing up to $225 million to add capacity the plants in Gurabo, Manati, and San Lorenzo.

TOPICS:

Threshold Reports Glioblastoma Data

October 1, 2012 5:15 pm | News | Comments

Threshold Pharmaceuticals Inc. has reported positive early-stage data for its drug TH-302 as a treatment for glioblastoma, the most aggressive type of brain cancer. The company said that so far, there are no side effects that limit dosing of the drug.

TOPICS:

Millipore in Stem Cell Collaboration

October 1, 2012 4:17 pm | News | Comments

EMD Millipore and the Institute of Bioprocess Engineering and Pharmaceutical Technology, Mittelhessen University of Applied Sciences announced a collaboration to develop optimized cell culture and harvesting processes for bioreactor-based stem cell cultures

TOPICS:
Advertisement

Vigabatrin Trial Results Delayed

October 1, 2012 4:04 pm | News | Comments

Catalyst Pharmaceutical Partners Inc. has been advised by the Department of Veterans Affairs Cooperative Studies Program that the availability of top-line results from Catalyst's vigabatrin Phase 2b trial for cocaine addiction will be delayed.

TOPICS:

Ruconest Trial Comes to a Close

October 1, 2012 3:38 pm | News | Comments

Biotech company Pharming Group NV announced that it has completed the clinical phase of the Phase 3 clinical study evaluating the investigational drug Ruconest for the treatment of acute attacks of angioedema in patients with hereditary angioedema.

TOPICS:

ACH-3102 Moving to Phase 2 Trials

October 1, 2012 3:30 pm | News | Comments

Achillion Pharmaceuticals Inc. announced positive proof-of-concept results for ACH-3102, a pan-genotypic NS5A inhibitor being developed for the treatment of chronic hepatitis C viral infections. Achillion has initiated a Phase 2 clinical trial evaluating ACH-3102 in combination with ribavirin for the treatment of patients with chronic GT 1b HCV.

TOPICS:

Independent Review Services

October 1, 2012 12:12 pm | Drug Discovery & Development | Product Releases | Comments

WorldCare Clinical LLC has announced its Endpoint Assessment Committee services for blinded independent central review of clinical trial data.

TOPICS:

Molecular Test

October 1, 2012 11:57 am | Product Releases | Comments

BD Diagnostics announced the release of a research use-only molecular test designed to rapidly detect antibiotic resistance genes found in the superbug known as carbapenem-resistant Enterobacteriaceae. These deadly organisms are resistant to nearly all antibiotics.

TOPICS:
Advertisement

Absorbance Reader

October 1, 2012 11:42 am | Product Releases | Comments

Berthold Technologies has released the Apollo 11, a dedicated absorbance reader. The instrument has continuously optimized optics as well as a modern LED light source. The optics and mechanical design, combined with the integrated auto-check function, guarantees accuracy.

TOPICS:

Apricus Will Seek MycoVa Approval

October 1, 2012 11:25 am | News | Comments

Apricus Biosciences Inc. will ask Canadian regulators to approve its antifungal drug MycoVa in late 2013. MycoVa is designed to treat onychomycosis, a persistent foot fungus infection that can cause pain as well as thickened and discolored toenails.

TOPICS:

Stryker Names New CEO

October 1, 2012 10:56 am | News | Comments

Medical device maker Stryker Corp. has named Kevin Lobo, the president of its orthopedics business, as its new president and CEO, effective immediately. Lobo has been with the company since April 2011. He previously held a variety of positions with Johnson & Johnson.

TOPICS:

IPP-204106 Moves to Phase 1/2

October 1, 2012 10:51 am | News | Comments

ImmuPharma plc, a specialist drug discovery and development company, announced that its cancer program IPP-204106 has begun further clinical trials with the next generation of polyplexed Nucant. The first patients have started dosing in this Phase 1/2 clinical trial.

TOPICS:

Another Blow to Amyloid Hypothesis

October 1, 2012 8:50 am | News | Comments

Researchers investigating a known gene risk factor for Alzheimer’s disease discovered it is associated with lower levels of beta amyloid—a brain protein involved in Alzheimer’s—in cognitively healthy older people, suggesting another mechanism may be involved.

TOPICS:

Blocking Protein Could Halt Immune Decline

September 30, 2012 3:00 am | News | Comments

The older we get, the weaker our immune systems tend to become, leaving us vulnerable to infectious diseases and cancer and eroding our ability to benefit from vaccination. Now, scientists have found that blocking the action of a protein whose levels in our immune cells rise with age can restore those cells’ response to a vaccine.

TOPICS:

New Humira Approval Granted

September 28, 2012 5:44 pm | News | Comments

Abbott Laboratories Inc. said the Food and Drug Administration approved its drug Humira as a treatment for ulcerative colitis in adults. The FDA approved Humira as a treatment for moderate to severe ulcerative colitis when other medicines have not worked.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading